Skip to main content

Table 1 Patient Characteristics

From: Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

Characteristics

No patients

ECOG performance status

   0

10

   1

11

   2

6

Age, years

   Median

68

   Range

49–88

Men/Women

9/18

Primary cancer

   Colorectal

8

   Breast

12

   Gastric

1

   Pancreas

2

   Others

4

Prior chemotherapy

   No of patients

21

   Range per patient

1–4

Prior radiotherapy

12

Prior endocrine therapy

6

Prior 5-FU

14

No prior therapy

6